Filing Flows › Biogen (BIIB) › R&D spending
Biogen (BIIB) R&D spending by quarter
Biogen's R&D spending was $574M in Q3 2026 (third quarter 2026), +8% from Q2 2026. Over the last 7 quarters it ranged from $399M (Q2 2025) to $574M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $574M | +8% | +32% |
| Q2 2026 | $530M | -2% | +33% |
| Q1 2026 | $539M | +6% | +24% |
| Q4 2025 | $509M | +17% | — |
| Q3 2025 | $436M | +9% | — |
| Q2 2025 | $399M | -8% | — |
| Q1 2025 | $434M | — | — |
Q3 2026 at a glance
Biogen, Q3 2026: revenue $2.8B (+11% year over year), operating margin -0.3%, net loss $20.6M, operating cash flow $641M. The chart follows the revenue to costs, profit and cash.
Questions
What is Biogen's R&D spending?
Biogen's R&D spending was $574M in Q3 2026 (third quarter 2026), +8% from Q2 2026.
How has Biogen's R&D spending changed?
Over the last 7 quarters it ranged from $399M (Q2 2025) to $574M (Q3 2026).